Phase 2b trial of add-on inhaled imatinib (10, 35 or 70 mg) vs placebo for 24 weeks in 202 adults with pulmonary arterial hypertension: no significant improvement in pulmonary vascular resistance, 6-minute walk or other secondary endpoints; cough rose with dose.
RCTn = 202 adults
Hill et al. Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension